APPLICATION
ANDA200626
TYPE
ANDA
ORIGINAL APPROVAL
2018-08-09
LATEST ACTION
2025-07-17
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued
Products
ATAZANAVIR SULFATEDiscontinued
ATAZANAVIR SULFATE EQ 300MG BASE · CAPSULE · ORAL
ATAZANAVIR SULFATEDiscontinued
ATAZANAVIR SULFATE EQ 150MG BASE · CAPSULE · ORAL
ATAZANAVIR SULFATEDiscontinued
ATAZANAVIR SULFATE EQ 200MG BASE · CAPSULE · ORAL
ATAZANAVIR SULFATEDiscontinued
ATAZANAVIR SULFATE EQ 100MG BASE · CAPSULE · ORAL
Approval history
2025-07-17Labeling · Supplement 6 · standardAP
2024-11-22Labeling · Supplement 5 · standardAP
2023-08-07Labeling · Supplement 3 · standardAP
2018-08-09Not Applicable · OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.